September 8, 2022
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a world immunology firm dedicated to enhancing the lives of folks affected by extreme autoimmune illnesses, introduced that through the extraordinary common assembly of shareholders held at the moment at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors.
Mrs. Sylvest brings sturdy strategic and operational management within the scaling of world business pharmaceutical organizations with a particular concentrate on firm tradition and sustainability. The voting end result and all paperwork relating to the shareholders’ assembly can be out there on the argenx web site at www.argenx.com/buyers/shareholder-meetings.
About argenx
argenx is a world immunology firm dedicated to enhancing the lives of folks affected by extreme autoimmune illnesses. Partnering with main educational researchers by its Immunology Innovation Program (IIP), argenx goals to translate immunology breakthroughs right into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only authorised neonatal Fc receptor (FcRn) blocker within the U.S., Japan, and the EU. The Company is evaluating efgartigimod in a number of severe autoimmune illnesses and advancing a number of earlier stage experimental medicines inside its therapeutic franchises. For extra info, go to www.argenx.com and observe us on LinkedIn, Twitter, and Instagram.
Media:
Kelsey Kirk
[email protected]
Investors:
Beth DelGiacco
[email protected]
